适应体:重新定位预定义的单克隆抗体与双特异的纳米体用于抗体治疗
Andrés González-Techera1, Gabriel Lassabe2, José A Chabalgoity3
1Departamento Interdisciplinario de Sistemas Costeros y Marinos, Centro Universitario Regional del Este, Universidad De La República, Rocha, Uruguay.
Biotechnology journal
|August 19, 2025
概括
适应体重新利用现有的单克隆抗体 (MoAbs) 进行新的治疗用途. 这种创新方法降低了开发成本,并加速了人类和兽医领域的创新.
科学领域:
- 生物技术是生物技术.
- 免疫治疗是一种免疫疗法.
- 纳米医学是一种纳米医学.
背景情况:
- 单克隆抗体 (MoAb) 疗法对于治疗各种疾病至关重要,但开发成本昂贵,耗时.
- 目前的MoAb开发是特定物种的,阻碍了兽医应用,并减缓了人类治疗创新.
研究的目的:
- 引入适应体,一种新的双特异性纳米体技术.
- 为了证明适应性,身体可以将现有的MoAbs重新用于新的治疗目标,从而减少开发负担.
主要方法:
- 开发了两种特定的纳米体结构 (适应体) 来将现有的MoAbs与新抗原相连接.
- 测试了该策略,使用模型小鼠MoAb重新定向到破伤风毒素.
主要成果:
- 通过Adaptabody介导的MoAb重定向到破伤风毒素使小鼠在致命剂量挑战时能够存活.
- 随着重新定位的MoAb剂量的增加,生存率增加,显示了剂量依赖的疗效.
- 该战略在概念验证研究中被证明是有效的.
结论:
- 适应体提供了一种灵活和可扩展的方法来创建新的治疗抗体.
- 这项技术降低了开发MoAb治疗的障碍,特别是在兽医中.
- 它使现有抗体的重新使用成为可能,加速治疗创新.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:31Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K